Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis have?
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis has 41 citations in the OpenAlex counts ScholarIQ stores.
When was Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis published?
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis has 2020 year in the ScholarIQ index.
What is the open-access status of Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis?
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis has closed oa status in the ScholarIQ index.
What is the DOI of Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis?
The DOI for Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis is on the source record.
What is the PMID of Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis?
The PMID for Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis is on the source record.
What is the OpenAlex record for Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis?
The OpenAlex for Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis is on the source record.